Skip to content
Other

Accounts Receivable, Chargebacks, Discounts And Fees

Moderna Accounts Receivable, Chargebacks, Discounts And Fees decreased by 30.4% to $126M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 173.7%, from -$171M to $126M.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026May 1, 2026
Metric ID: other_accounts_receivable_chargebacks_discounts_and_fees

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0-$479M-$692M-$285M-$329M-$1.17B$340M-$171M$212M$975M$181M$126M
QoQ Change-44.5%+58.8%-15.4%-255.0%+129.1%-150.3%+224.0%+359.9%-81.4%-30.4%
YoY Change-143.8%+149.1%+40.0%+164.4%+183.5%-46.8%+173.7%
Range-$1.17B$975M
Avg YoY Growth+74.3%
Median YoY Growth+149.1%
Current Streak2 quarters decline

Frequently Asked Questions

What is Moderna's accounts receivable, chargebacks, discounts and fees?
Moderna (MRNA) reported accounts receivable, chargebacks, discounts and fees of $126M in Q1 2026.
How has Moderna's accounts receivable, chargebacks, discounts and fees changed year-over-year?
Moderna's accounts receivable, chargebacks, discounts and fees increased by 173.7% year-over-year, from -$171M to $126M.